Were you diagnosed with Relapsed or Refractory Multiple Myeloma? Has the disease come back, even after multiple treatments?
Were you diagnosed with Relapsed or Refractory Multiple Myeloma? Has the disease come back, even after multiple treatments?
About Relapsed or Refractory Multiple Myeloma
Multiple myeloma is a cancer that affects a type of white blood cell, called a plasma cell, that helps the immune system fight infections. Sometimes, a cancer will respond to treatment but then become resistant to the treatment and start growing again. When this happens with multiple myeloma, it is called Relapsed or Refractory Multiple Myeloma1.
Currently, there are few treatment options for people with relapsed or refractory multiple myeloma. Approved treatments may include medications that can slow down how fast the myeloma cells multiply, medications that block how fast myeloma can grow and medications that can help the immune system fight the myeloma1.
Are 18 years of age or older.
Were diagnosed with relapsed or refractory multiple myeloma.
Have tried at least 2 lines of therapy for your multiple myeloma in the past.
Have NOT received a prior therapy that targets BCMA.
Our Study
An investigational drug is being studied for use in patients who have relapsed or refractory multiple myeloma. The investigational drug is not approved by the United States Food and Drug Administration (FDA), or any other global regulatory agency and the safety and effectiveness are under evaluation.
Our investigational drug called ABBV-383, is being studied in patients with relapsed or refractory multiple myeloma to determine if it is safe and effective when given via an intravenous infusion (an infusion given through the vein) at monthly intervals.
The purpose of this study is to compare the investigational drug itself against standard available therapies for multiple myeloma and to find out if anti-tumour activity can be seen with ABBV-383 alone. If so, we want to see how it compares to these other standard available therapies. In the Cervino Study, participants will be randomly assigned (like the flip of a coin) to receive the investigational drug or will be given a standard available therapy that will be chosen by their doctor. Study participants will be followed closely with clinic visits and tests.
